Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 15/20 | 0.74 |
| ▸ | PDE4B | Q07343 | 16/20 | 0.67 |
| ▸ | PDE4A | P27815 | 11/20 | 0.67 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7352455 | 0.91 | PDE4D (0.70) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL6862980 | 0.89 | PDE4B (0.66) | PDE4DPDE4BPDE4APDE4CMAPK14 | |
| SCHEMBL7334253 | 0.89 | PDE4D (0.70) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL7335619 | 0.89 | PDE4D (0.70) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL7334257 | 0.89 | PDE4D (0.70) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL6863990 | 0.87 | PDE4D (0.62) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL7359952 | 0.87 | PDE4D (0.67) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL6858785 | 0.86 | PDE4B (0.66) | PDE4DPDE4BPDE4APDE4CMAPK14 | |
| SCHEMBL1026961 | 0.86 | PDE4D (1.00) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL6864734 | 0.85 | PDE4D (0.56) | PDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0652868-B1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE | AVENTIS PHARMA LTD (GB) | 2004-11-10 | — | — | EP | claimed |
| EP-2044023-B1 | DERIVATIVES OF 1-PHENYL-2-PYRIDYNYL ALKYLENE ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMA SPA (IT) | 2011-01-19 | — | — | EP | disclosed |
| US-7671066-B2 | Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-03-02 | — | — | US | disclosed |
| EP-2044023-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDYNYL ALKYLENE ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.p.A. (IT) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008006509-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDYNYL ALKYLENE ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2008-01-17 | — | — | WO | disclosed |
| US-20080015226-A1 | Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.P.A.. | 2008-01-17 | — | — | US | disclosed |
| WO-2005018563-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A PHOSPHODIESTERASE INHIBITOR FOR THE TREATMENT OF ISCHEMIC MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| EP-0652868-B1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE | AVENTIS PHARMA LTD (GB) | 2004-11-10 | — | — | EP | disclosed |
| WO-2004047817-A1 | PDE4 AND PDE3/4 INHIBITORS FOR USE IN THE TREATMENT OF CACHEXIA | ALTANA PHARMA AG (DE) | 2004-06-10 | — | — | WO | disclosed |
| WO-2003024488-A2 | COMBINATION OF A PDE INHIBITOR AND A LEUKOTRIENE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | disclosed |
| US-5935978-A | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group | RHONE-POULENC RORER LIMITED (GB) | 1999-08-10 | — | — | US | disclosed |
| US-5840724-A | COMPOUNDS FOR TUMOR NECROSIS FACTOR OR ENZYME INHIBITORS OF PHOSPHODIESTERASES | RHONE-POULENC RORER LIMITED (GB) | 1998-11-24 | — | — | US | disclosed |
| EP-0741707-B1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE POULENC RORER LTD (GB) | 1998-04-01 | — | — | EP | disclosed |
| US-5698711-A | INHIBITORS OF TUMOR NECROSIS FACTOR, CYCLIC ADENOSINE-3*,5*-MONOPHOSPHATE PHOSPHODIESTERASE AND EOSINOPHILS | RHONE-POULENC RORER LIMITED (GB) | 1997-12-16 | — | — | US | disclosed |
| US-5693659-A | Substituted oxime derivatives and processes for their preparation | CELLTECH THERAPEUTICS LIMITED (GB) | 1997-12-02 | — | — | US | disclosed |
| US-5679696-A | FOR INHIBITING TUMOR NECROSIS FACTOR; ENZYME INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1997-10-21 | — | — | US | disclosed |
| EP-0741707-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995020578-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1995-08-03 | — | — | WO | disclosed |
| EP-0652868-A1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF | RHONE-POULENC RORER LIMITED (GB) | 1995-05-17 | — | — | EP | disclosed |
| WO-1994002465-A1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF | RHONE-POULENC RORER LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015226-A1 | Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors | PDE4A, PDE4B, PDE12 | PDE4D 9/4885PDE4B 2/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.